Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use

ABSTRACT

Pharmaceutical dosage unit compositions containing as an active ingredient a compound of the formula   WHEREIN R and R1 may be the same or different and are selected from the group consisting of hydrogen and straight and branched alkyl of 1 to 6 carbon atoms and taken together with the nitrogen atom to which they are attached form a saturated 5 to 7 member heterocyclic ring which can optionally contain an oxygen or nitrogen heteroatom and may be substituted with alkyl of 1 to 6 carbon atoms or hydroxyl, R2 is selected from the group consisting of hydrogen and straight and branched alkyl of 1 to 6 carbon atoms, R3 is selected from the group consisting of methyl in in the 6or 7-position and hydrogen and A is a straight or branched alkylene of 2 to 10 carbon atoms OR A NON-TOXIC, PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; AND METHODS OF USING THE SAME FOR INHIBITING PLATELET AGGREGATION IN WARM-BLOODED ANIMALS.

United States Patent [191 Woitun et al.

May 13, 1975 Wolfgang Schriiter, all of Biberach an der Riss, Germany [73] Assignee: Boehringer lngelheim G.m.b.H.,

lngelheim am Rhein, Germany [22] Filed: Aug. 22, 1974 [2]] Appl. No.: 499,460

Related U.S. Application Data [62] Division of Ser. No. 60,933, Aug. 4, 1970, Pat. No.

OTHER PUBLICATIONS Thomae, Chem. Abstracts, Vol. 67, p. lO0l49g (1967).

Primary ExaminerStanley J. Friedman Attorney, Agent, or Firm-Hammond & Littell [57] ABSTRACT Pharmaceutical dosage unit compositions containing as an active ingredient a compound of the formula wherein R and R, may be the same or different and are selected from the group consisting of hydrogen and straight and branched alkyl of l to 6 carbon atoms and taken together with the nitrogen atom to which they are attached form a saturated 5 to 7 member heterocyclic ring which can optionally contain an oxygen or nitrogen heteroatom and may be substituted with alkyl of l to 6 carbon atoms or hydroxyl,

R, is selected from the group consisting of hydrogen and straight and branched alkyl of l to 6 carbon atoms,

R; is selected from the group consisting of methyl in in the 6- or 7-position and hydrogen and A is a straight or branched alkylene of 2 to ID carbon atoms or a non-toxic, pharmaceutically acceptable acid addition salt thereof; and methods of using the sane for inhibiting platelet aggregation in warm-blooded animals.

ll Claims, No Drawings 1 PHARMACEUTICAL COMPOSITIONS CONTAINING A Z-(AMINOALKYLAMINO)-4-AMINO-THIENO[3,2- D]PYRIMIDINE AND METHOD OF USE This is a division of copending application Ser. No. 60,933 filed Aug. 4, 1970, now US. Pat. No. 3,838,12l.

This invention relates to novel pharmaceutical compositions containing as an active ingredient a 2- (aminoalkylamino)-4-amino-thieno[3,2-dlpyrimidine or a non-toxic acid addition salt thereof, as well as to methods of using the same as platelet aggregation inhibitors.

More particularly, the present invention relates to novel pharmaceutical dosage unit compositions consisting essentially of an inert pharmaceutical carrier and an effective platelet aggregation inhibiting amount of a compound of the formula wherein R and R, may be the same or different and are selected from the group consisting of hydrogen and straight and branched alkyl of 1 to 6 carbon atoms and taken together with the nitrogen atom to which they are attached form a saturated 5 to 7 member heterocyclic ring which can optionally contain an oxygen or nitrogen heteroatom and may be substituted with alkyl of l to 6 carbon atoms or hydroxyl, R is selected from the group consisting of hydrogen and straight and branched alkyl of l to 6 carbon atoms,

R is selected from the group consisting of methyl in the 6- or 7-position and hydrogen and A is a straight or branched alkylene of 2 to l carbon atoms or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Among the preferred compounds of formula I are those where R and R together with the nitrogen atom to which they are attached, form a morpholino ring optionally substituted with a methyl group.

The acid addition salts of the thieno [3,2- d]pyrimidines of formula I may be derived from nontoxic, pharmaceutically acceptable inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc., and organic acids such as succinic acid, tartaric acid, maleic acid, fumaric acid, etc.

The thieno[3,2-d]pyrimidines of formula 1 may be made by the following methods.

Method A By reaction of a compound of the formula wherein R, R, and R have the above meanings and Z is a halogen atom, a substituted mercapto group or an alkylsulfonyl group with a diamine of the formula (III) XHN A N H wherein R and A are as defined above and X is a hydrogen atom or a protecting group easily split off, for example, acetyl, benzoyl or p toluenesulfonyl group, and optionally splitting off the protecting group X.

If the radical Z is a halogen atom, the presence of a hydrogen halide binding agent is required.

The reaction is performed at temperatures between 20 and 200C, preferably in the presence of an organic solvent. The hydrogen halide binding agent may be an inorganic or tertiary organic base. There may, however, also be used at least a molar excess of the employed diamine of general formula III as acid binding agent. A further excess of the diamine may serve as the solvent. if X represents a protecting group, this is split off subsequently, for example by means of hydrolysis.

Method B By reaction of a compound of the formula wherein the radicals R R X and A have the above meanings and Z is a halogen atom, a free or substituted mercapto group or an alkylsulfonyl group with an amine of the formula wherein R, and R are as defined above, and optionally splitting off a protecting group X. If Z is a halogen atom, the presence of a hydrogen halide binding agent is required for the reaction.

The reaction is performed at temperatures between 20 and 200C, preferably in the presence of an organic solvent. The hydrogen halide binding agent may be an inorganic or tertiary organic base. There may, however, also be used at least one molar excess of the employed amine as acid binding agent. A further excess of this amine may serve as the solvent. If X is a protecting group, this is optionally subsequently split off, for example by means of hydrolysis.

Method C By reaction of a compound of the formula l z AN---( n R k ks (v1) //N wherein the radicals R to R and A are defined as above and Z is a halogen atom, with ammonia or with a carboxylic acid amide or a carboxylic acid imide or their metal salts and by subsequent splitting off of the acid group from the originating carboxylic acid derivative.

The reaction is performed at temperatures between and 200C, preferably in the presence of an organic solvent. When reacting with ammonia, the reaction is preferably carried out with an excess of ammonia in a closed vessel. The carboxylic acid derivative formed when using a carboxylic acid amide or imide is split with acids or bases. Bases especially suitable are hydrazine and hydroxylamine.

Method D By catalytic reduction of a nitrile of the formula Method E Compounds of the formula I in which R and R together with the nitrogen atom form a morpholino ring optionally substituted by an alkyl group, are produced by intramolecular cyclization ofa compound of the formula wherein the radicals X, R R and A are defined as above and R, and R are hydrogen atoms or one of R or R is an alkyl of l to 6 carbon atoms and the other is a hydrogen atom in the presence of an acid conden sation agent, and optionally splitting off a protecting group X.

The reaction is carried out in the presence of an acid condensation agent and optionally in a solvent at temperatures between 0 and C. The condensation agent may be acids such as sulfuric acid, phosphoric acid, perchloric acid, hydrochloric acid, hydrobromic acid, toluene sulfonic acid or anhydrous metal salts such as zinc chloride or a cation exchanger. The solvents may be higher hydrocarbons such as tetraline or the acid used as condensation agent such as sulfuric HOOC or a reactive derivative thereof is reacted with urea or thiourea or cyanic or thiocyanic acidv The reactive derivatives of the 3-aminothiophene-Z-carboxylic acid proved to be especially suitable are the esters and amides thereof. This forms compounds of the formula wherein R, has the above meanings and B is a free hydroxy or mercapto group. If urea or cyanic acid is re acted with a compound of formula IX, there is formed a compound of formula X, wherein B is a free hydroxy group. If thiourea or thiocyanic acid is used there is obtained a compound of formula X, in which B is the free mercapto group. These reactions are generally performed at elevated temperatures, preferably at temperatures between 20 and 200C and optionally in the presence of water. when cyanic or thiocyanic acid is used, or in the presence of an inert, high-boiling solvent such as toluene, xylene or tetrahydronaphthalene.

The compounds of formula ll, in which 2 is a halogen atom, are produced by converting compounds of for mula X, in which B is a free hydroxy group, by conventional methods, for example by heating with a phosphorus halide, first into a compound of the general formula 1 Hal in which Hal is a halogen atom. These compounds are then reacted at room temperature or at slightly elevated temperatures in a solvent, for example in ethanol, with compounds of formula V. Thus, the starting compounds of formula II, wherein the radicals R R and R are defined as above and Z is a halogen atom, are formed.

For the production of compounds of formula II, in which 2 is an alkylmercapto or alkylsulfonyl group, compounds of formula X, in which-B is a free mercapto group, are converted by conventional methods, by treating with alkylation agents, for example dialkylsulfates or alkylhalides, into the corresponding 2- alkylmercapto-4-hydroxy-thienol3,2-dlpyrimidines. These compounds are converted by known methods, for example, by heating with a phosphorus halide, into compounds of the formula wherein Alkyl is any alkyl group and Hal is a halogen atom. These compounds are subsequently reacted at room temperature or at slightly elevated temperatures in a solvent, for example in ethanol, with compounds of formula V. Thus the starting materials of formula II, wherein the radicals R R and R are defined as above and Z is an alkylmercapto group, are formed. The thus obtained compounds of formula II may subsequently be converted if desired, by means of oxidation agents, for example chlorine or potassium permanganate, into such compounds of formula II in which Z is an alkylsulfonyl group.

Compounds of general formula III, wherein X is at protecting group, such as for example, acetyl, benzoyl or p-toluenesulfonyl group, are produced according to methods known from the literature (see Houben-Weyl, vol. XI/l, page 26 ff).

The compounds of formula IV are produced, for example, by reaction of a 3-amino-thiophene-2- carboxylic acid of formula IX or a reactive derivative thereof with thiourea or thiocyanic acid. The reactive derivatives of the 3-aminothiophene-Z-carboxylic acid which proved to be especially suitable are their esters and amides. Thereby are formed 2-mercapto-4-oxythieno[3,2-d]pyrimidines in which the free mercapto group is subsequently alkylated by means of alkyl halides to obtain 2-alkylmercapto-4-oxy-thieno[3,2- d]pyrimidines which are reacted with diamines of formula lll,

XHN-A-N-H wherein R X and A are defined as above, to the corresponding 2-aminoalkylamino-4-oxi-thieno[3,2- dlpyrimidines, after optionally splitting off the radical X. These pyrimidines are subsequently halogenated by means of phosphoroxyhalides to the starting materials of formula IV, in which Z is a halogen atom, or they are, for example, converted by means of diphosphoruspentasulfide into the corresponding starting compounds of formula IV having a mercapto group in 4- position. The thus obtained starting compound of formula IV may subsequently be alkylated, if desired, by means of alkyl halides by conventional methods to form a compound of formula IV, in which Z is an alkylmercapto group. These compounds can easily be oxidized to compounds of formula IV, in which Z is an alkylsulfonyl group. The oxidation is preferably carried out by means of chlorine or potassium permanganate.

The starting materials of formula VI are obtained by reaction of 2-hydroxyalkylamino-4-amino-thieno[3,2- d]pyrimidines of the formula wherein the radicals R to R and A are defined as above with halogenation agents such as thionyl chloride. The reaction may be perfomed in an inert solvent. The compounds of formula XIII are known from the German Offenlegungsschrift No. 1,470,356 or may be produced by the methods described therein.

The starting materials of formula VII are obtained by reaction of aminonitriles of the formula mm a v A CN wherein R is defined as above and A has the meaning of A minus a methylene group, with compounds of formula II. The aminonitriles of formula XIV are partially known from the literature or may be produced by methods described in the literature (Houben-Weyl, Vol. XI/l, page 272 ff).

The starting materials of formula Vlll may be produced from a 2,4-dichloro-thieno[3,2-d1pyrimidine of formula XI by reaction with a diethanolamine and subsequently with an amine of formula III. If X represents a protecting group, this may subsequently be split off hydrolytically.

The novel compositions of the invention for inhibiting aggregation of platelets are comprised of a compound of formula I or its non-toxic, pharmaceutically acceptable acid addition salts and a major amount of a pharmaceutical carrier. The compositions may be in the form of drinkable or injectable solution or suspensions, tablets, coated tablets, drops, etc. The usual individual dose is 5 to I00 mgm, preferably 10 to 50 mgm, of the active ingredient and the daily dose is I00 to 200 mgm per day of the active ingredient.

The method of the invention for inhibiting aggregation of platelets in warm-blooded animals comprises administering to warm-blooded animals an amount of a compound of formula I or its non-toxic, pharmaceutically acceptable acid addition salts sufficient to inhibit aggregation of platelets. The said compounds may be administered transcutaneously or orally. The usual daily dose is I00 to 200 mgm/kg.

In the following examples, Examples l to XIV show the preparation of starting materials and Example I to 15 show the preparation of final products.

EXAMPLE I L6 gm (0.0l mol) of methyl 3-aminothiophene-2- carboxylate and 3 gm (0.05 mol) of urea were admixed and then heated for 2 hours at 200C to obtain a clear brown melt which solidified when cooled. The said product was dissolved in warm 2N aqueous sodium hydroxide and the solution was decolorized with charcoal 5 and made acidic with 2N hydrochloric acid. The mix- U i h same procedure, phosphorus oxychloride ture was vacuum filtered to recover the crystalline pr ewas a ted with 2,4-dioxy-6-methyl-thieno[3,2- eipitate which was recrystallized from water to obtain pyrimidine and z,4 dioxy 7 memyl thien0[32 n I yield) A- Y IM- dlpyrimidine to obtain 2,4dichloro-6-methyllpy melhng at more than 300 thieno[3,2-d]pyrimidine melting at 150C and 2,4-

dichloro-7-methyl-thieno[3,2-d]pyrimidine melting at l86C respectively.

Analysis: C H N O S; molecular weight I68.l8 Calculated: C6- 32. 84 l-l 2.40%; N 16.66%; EXAMPLE 1" C 175% 157%; N 682% 5.1 gm of 0.025 mol) of 2.4-dichloro-thieno[3,2-

d]pyrimidine was added to 200 cc of absolute ethanol Using the same procedure, urea was reacted with n gm (0'055 9 ofmorplilolmfi w add ed methyl 3 amino 5 methyl thiophene 2 Carb0xylate and stirring to the resulting suspension while keeping the a methyl 3 amin0 4 methyMhioPhenez carboxylate o temperature at 20 C with cooling. The resulting clear form 2 4 dioxy 6 melhyl thieno[3 2 d]pyrimidine solution was allowed to stand for a short while during melting aove 320C and 2 which a crystalline compound precipitated out and thienow 2 d]pyrimid-me ;nemng abclve 300C respec then the reaction mixture was stirred for 2 hours. After tively vacuum filtration, the crystalline precipitate was washed with water, then ethanol. The product was re- EXAMPLE ll crystallized from methyl ethyl ketone to obtain 5.75 gm A mixture of 8.4 gm (0.05 mol) of 2.4-dioxy-thieno 3 Xif 2-61]lOr%;4 r;0%hO]mO-th'en0[3'2- [3.2 d]pyrimidine and cc of phosphorus oxychlolpynm me me at 19 8 ride was refluxed for l0 hours to obtain a clear solution and excess phosphorus oxychloride was distilled off in 3D vacuo. The residual oil was added to an ice-water mix- Analysis: W m M molecular Wight 255374 ture and then the mixture was extracted with chloroggfigf :jgggi 1233;; form. The chloroform extract was washed with water until the wash waters were neutral, dried over sodium sulfate and distilled to dryness. The residue was erystal- 35 Using the same procedure, the appropriate 2,4- lized from ethanol to obtain 7.6 gm (74% yield) of 2,4- dichloro-thieno[3,2-dlpyrimidine was reacted with the dichloro-thieno{3.2-dlpyrimidine melting at l4 1 to appropriate amino compound to obtain the products in [42C. Table I.

TABLE I Product Melting point Crystallization in "C from 2-chloro-6mcthyl-4-morpholino -thieno[ 3.2-d lpyrimidine l8() 1 Bl acetone 2-chloro-4-(2-methyl-rnorpholino) -thieno[ 3,2-dlpyrimidine l69-l 7l ethanol 2-chloro-4-(4-hydroxypiperidino)-thieno[3.2-d] yrimidine 176-178 butnnol 2-chloro-4-(4-methy -piperazino)-thieno[3.2-d[pyrimidine l [ti-I20 ethanol 2-chlore-4-pyrrolidino-thieno [3,2 d]pyrimidine 179-[80 ethanol 2-chloro 4-hexamethyleneimino -thienol 3 ,Z-dIpyrimidinc 89-90 ethanol 2-chl0ro-4-aminothieno[3.241] pyrimidine 273-275 ethanol 2-chloro-4-(n-pentylamino)- absolute thieno[3.2-d]pyrimidine HCI 206-208 ethanol 2-chloro-4-diethylamino-thieno petroleum [3.2-d1pyrimidine l04-l05 ether 2-ehloro-4-piperidino-thieno (3,2-d Ipyrimidinc l27l 28 ethanol 2-chloro-4-dimcthylaminothienol 3,2-d lpyrimidinc 163 acetone 2-chloro-4methylnmino-thieno acetone! [3.2-dlpyrimidine 253 ethanol (|:l) 2-chloro-4-n-propyluminopetroleum eththicno[ 3.2-d Ipyrimidinc 96 er/ethyl acelate l0:l 2 chloro-7-mcthyl 4-murpholin0 -thieno{ 3.2-d lpyrimidine 128 ethanol EXAMPLE IV A solution of 19.4 gm (0.2 mol) of potassium thiocyanate in 20 cc of water were added dropwise with stirring over 30 minutes to a solution of 15.7 gm (0.1 mol) of methyl 3-amino-thiophene-Z-carboxylate in 150 cc of hydrochloric acid warmed to 70C and white crystals immediately began precipitating. The reaction mixture was heated for 2 5% hours at 95C and the reaction mixture was vacuum filtered. The crystalline precipitate was dissolved in 250 cc of 2N aqueous sodium hydroxide with heating. The cooled solution was acidified with glacial acetic acid whereby an analytically pure compound precipitated out. After vacuum filtration, the crystals were washed with water and dried to obtain 14.9 gm (81% yield) of 2-mercapto-4-oxy-thieno[3,2- d]pyrimidine melting above 300C.

Analysis; C H N Os molecular weight 184.25

Calculated: C 39.12%; H 2.19%

Found: C 39.20%; H 2.21%

EXAMPLE V Analysis: C HJJ OS molecular weight 212.30

Calculated: C 45.26%; H 3.80%; S 30.21%

Found: C 45.40%; H 3.85%; S 30.13%

EXAMPLE V1 A mixture 0f 2.1 gm (0.011 mol) of Z-ethyl mercapto-4-oxy-thieno[3,2-d]pyrimidine and 60.0 gm (1.0 mol) of 1,2-diamino ethane was heated for hours at 160C in a sealed tube. After cooling the reaction mixture, the excess amine was distilled off in vacuo. The residue was subjected to chromatography over a column of 0.2 0.5 mm silicagel with elution with a 7:3

mixture of chloroform/methanol. The pure fractions were evaporated to dryness and the residue was crystallized from a petroleum ether/ethanol mixture to obtain 0.59 gm (28% yield) of 2-(2-aminoethylamino)-4-oxy- 5 thieno[3,2-d]pyrimidine melting at 221C with decomposition.

EXAMPLE V11 A mixture of 2.1 gm (0.01 mol) of 2-(2-aminoethylamino)-4-oxy-thieno[3,2-d]pyrimidine and 30 cc of phosphorus oxychloride was refluxed for 2 hours and excess phosphorus oxychloride was distilled off in vacuo from the resulting clear solution. The residue was dissolved in water and the aqueous solution was made alkaline with aqueous sodium hydroxide solution with ice cooling. The aqueous phase was extracted with methylene chloride and the organic extracts were washed with water until the wash waters were neutral and then dried over sodium sulfate and distilled to dryness. The solid residue was crystallized from ethanol to obtain 0.48 gm (21% yield) of 2-(2-aminoethylamino )-4-chloro-thieno[ 3.2-d]pyrimidine melting above 300C.

Analysis: C,,H,C1N,S; molecular weight 228.72 Calculated: C 42.01%; H 3.97%; C1 15.50% Found: C 42.30%; H 4.06%; CI 15.75%

EXAMPLE VI Analysis: C H N O S; molecular weight 322.44 Calculated: C 55.87%; H 6.88%; N 17.38% Found: C 55.79%; H 6.81%; N 17.50%

Using the same method, the appropriate thieno [3,2-

d]pyrimidine and amino alcohol were reacted to obtain the compounds of Table 11.

pyrimidine HCl EXAMPLE x 2.16 gm (0.01 mol) of 2-methylmercapto-4- chlorothienol3,2-dlpyrimidine (produced from phos- 14 The solid product was washed with water and crystallized from dimethyl formarnide to obtain 0.) gm (40% yield) of 2-(2-aminoethylamino)-4-mercaptothieno[3,2-d]pyrmidine melting at 249-250C (dephorus oxychloride and 2-methylmercapto-4-oxythieno[3,2-d]pyrimidine melting at 7173C) were 5 added to 30 cc of absolute ethanol and then 1.74 gm (0.02 mol) of morpholine were added with stirring to the reaction mixture while cooling to 20C. The reac- Analysisi 8 lt| 4 2i molecular wei 226-23 tion mixture was then stirred for 3 hours at room tem- 1O gglf fli :21:23 3 I iii- I 51:23: perature and was then vacuum filtered. The precipitate was washed with water and then ethanol and crystallized from ethanol to obtain 2.05 gm (77% yield) of 2- methylmercapto-4-morpholino-thieno [3,2- EXAMPLE d]pyrimidine melting at l38-l40C. l5 2.26 gm (0.0] mol) of 2-(2-aminoethylamino)-4- mercapto-thieno[3,2-d]pyrimidine were dissolved in 40 cc of 0.25N potassium hydroxide solution and after I I cooling to 0C, 1.42 gm (0.01 mol) of methyl iodide 3523:55 ''Pfi'iig Tf'fji'filfi were added thereto with stirring. An oil soon separated Found: C H 5 N 5.84% and stirring was continued for 2 hours at 0C. The mixture was extracted several times with chloroform and the combined extracts were washed with water, dried EXAMPLE x] over sodium sulfate and evaporated to dryness. The residue was crystallized from ether to obtain 1.9 gm A 801mm of gm of potasslum P 79% yield) of 2-(2-aminoethylamino)-4-methylmermanganate in 25 cc of water was added dropwise over 25 Capto thieno [3,2 d]pyrimidine mating at 75C 15 minutes to a solution of 2.67 gm (0.01 mol) of 2- methylmercapto-4-morpholino-thienol3,2- dlpyrimidine in 25 cc of glacial acetic acid and the reaction mixture was then stirred for 2 hours at 25C. ANALYSISI il l2 4 2i molecular Weight 240736 The solution was decolored with a sodium bisulflte so- %C 4436 %H %N 233] lution and was then made alkaline by the addition of D: 513 ill 23.18 aqueous sodium hydroxide solution. The aqueous phase was extracted several times with methylene chlo- EXAMPLE XIV ride and the combined methylene chloride phases were washed with water, dried over sodium sulfate and evap- A mixture of gm of zrchlorori'mor' orated to dryness in vacuo. The residue was crystallized pholino-llhienol lpy and 20 cc of f ethanol to obtain 4 gm 2% yield) f 2- butylamino-propionitrile was heated at 150C for 10 methylsulfonyl-4-morpholino-thieno[3.2-dlpyrimidine hours and excess y -p p t making at g t gyc was distilled off in vacuo. The residue was poured into 40 water and the mixture was extracted several times with methylene chloride. The methylene chloride extracts were dried over sodium sulfate and evaporated to dryd' b j z i g ifl kzggg f '2% ness. The residue was purified by chromatography over Found: c 44119 101 H 445%; N 1319095 a silica gel column with elution with a 2l mixtrue of petroleum ether and ethylacetate. The elution agent was distilled off and the resulting yellow oil was dissolved in methanolic hydrochloride and the addition of EXAMPLE acetone caused the precipitation of 5.0 gm (64.4% A mixture of 2.1 gm (0.01 mol) of 2-(2- yield) of 2-[(2- cyanoethyl-nbutylamino[-4- aminoethylamino)-4-oxy-thieno[3,2-d]pyrimidine and morpholino-thieno [3.2-d1pyrimidine hydrochloride 2.5 gm (0.01 1 mol) of phosphorus pentasultide in 25 which melted at l82-l85C after crystallization from cc of absolute pyridine was refluxed for 4 hours and the isopropanol.

ANALYSIS: C|7H,4N ,CIOS; molecular weight 381.96

CALCU- %C 53.45 %H 6.33 %N 18.33 %Cl 9.27 %s 8.38

LATED:

FOUND: $3.50 6.5) 18.45 9.02 8.33

resulting clear solution was evaporated to dryness in Using the same procedure, 2-chloro-4-morpholinovacuo. The residue was added to 20 cc of water and the thienol 3,2-d1pyrimidine was reacted with 3- mixture was refluxed for 1 hour and then was colled to ethylaminopropionitrile and 3-methylamino-propioni 5C. The pH of the solution was adjusted to 12 by the to form 2-[(2-cyanoethyl)ethylaminol-4-morpholinoaddition of2N aqueous sodium hydroxide and was then thieno 1 2 1 pyrimidine hydrochloride melting at filtered through charcoal. Glacial acetic acid was C and -ll l' y l y ladded to the solution which caused the formation of a precipitate which was recovered by vacuum filtration.

morpholino-thieno [3.2-dlpyrimidine hydrochloride melting at l00101C, respectively.

EXAMPLE 1 A mixture of 5.12 gm (0.02 mol) of 2-chloro-4-morpholino-thienol3,2-dlpyrimidine and cc of 1,2- diaminoethane was heated for minutes at C and after cooling. the reaction mixture was poured into a water-ice mixture. The aqueous solution was made strongly alkaline by the addition of a 30% aqueous sodium hydroxide solution and was then extracted several times with methylene chloride. The combined organic extracts were washed with water, dried over sodium sulfate and evaporated to dryness. The non-crystalline residue was purified by chromatography over a silica gel column with elution with acetone-methanol (7-3) mixture and the pure fractions were evaporated to dryness. The non-crystalline residue was dissolved in absolute ether and precipitation was effected by addition of etheral hydrochloric acid. The precipitate was recovered by vacuum filtration. was washed with ether and was crystallized from absolute ethanol to obtain 4.5 gm (64% yield) of 2-(2-aminoethy1amino)-4-morpholinothieno[3,2-d]pyrimidine dihydrochloride melting at 282-283C (decomp).

ANALYSIS: C H N Os 2HC1 molecular weight 352.30 CALCU- %C 40.92 %H 5.44 %N 19.88 %Cl 20.13 LATED:

FOUND: 40.90 5.49 19.79 20.05

Using the same process, the appropriate thieno [3,2- dlpyrimidine and diamino alkane were reacted to form the products of Table IV.

TABLE IV Melting Solvent of PRODUCT Point Crystallizain C tion Z-(Z-aminoethylamino)-6-methy| 309-31 1 methanol -4-morpholino-thienol 3.241] (decomp) pyramidine 2HCl 2-[ 2-aminoethyl )rnethylaminol 27 5 ethanol -4morpholino-thieno[ 3,2-dl ldccomp) pyrimidine-2H0 2-( 2-aminopropylamino )-4-mor- 214-216 ethanol polino-thicnol3,2-dlpyrirnidine (dccomp) 2HC1 2-(2-amino-l-methyl propylamino) isopropanol -4morpholino-thicno[ 3,2-dl (dccomp) pyramidine-ZHCI 2-( 3-aminopropylamino )-4-morpho- 255-258 ethanol lino-thienol 3,2-dlpyrimidine (decomp) 2HC1 2-(4-aminobutylamino)-4-morph0- 245-247 methanollino-thienol 3 ,Z-dlpyrimidine (decomp) methyl-ethyl -2HCl ltetone(12) 2-(fi-aminohexylamino)-4-morpho- 280-282 ethanollino-thien0{3.2-dipyrimidinc (decomp) acetone -2HCl l-1 2-( lO-aminodecylamino)-4morpho- 184-186 isopropanollino-thieno[3,2-dlpyrimidine (decomp) acetone -2HCl [-2) 2-( 3-aminopropylamino)-4-amino- 129-130 ethanol thieno[3.2-d]pyramidine 2-( Z-aminocthylamino )-4-pentyl- 273-275 ethanol amino-thicno[3,2-dlpyrimidine- (decomp) 2-( 4-aminobutylamino )4-n-propyl- 216-217 ethanol amin0-thieno[3,2dlpyrimidine-2 acetone HCI l-3 l 2-( Z-aminocthylamino )-4-( Z-methyl- 276-278 ethanol morpholinol-thicnol3.2-dlpyrimi- (decomp) dine 2HC1 2-( Z-aminocthylamino)-4-(4- 183-186 methanol methylpipcrazino )-thienol 3,2-d] (dccomp) pyrimidine 3HC1 2-(2-aminoethylamino)-4-(4- 247-249 ethanol hydroxypiperidino-thienol 3,2-d] (decomp) pyrimidine-ZHC] 2-(4-aminobutylamino )-4-hexa 123-125 ethanolmethyleneimino-thienol 3,2-d] (decomp) acetone pyrimidine-2H0 (l-2l 2-(Z-aminoethylamino)-4-pipori- 275-277 ethanoldino-thicnu[3.2-dlpyrimidine acetone 2HCl -5l 2-( 4-aminobutylamino J-4-piperidino- 21) ethanolthienol 3.2-:1 lpyrimidinc-ZHC! acctsone 11-. l 2-(6-aminohexylamino)-4-piperidino- 28 l-283 ethanol-ace thienol3.2-dlpyrimidine-2HC1 tone(1-S) 2-( 3-aminopropylamino l-4-dimcthyl- 269-271 methanol amino-thienol 3.2-d Ipyrimidine-2HCl 2-[4-aminobutylamino)-4-dimethyl- 280 ethanol amino-thienol 3.2d lpyrimidine-IZHCI 2-[6-aminohexylamino)-4-dimcthyl- 265-266 ethanolamino-thicnol3,2-dlpyrimidinc-2HCI acetone 2-[4-uminohutylaminn)-6 methyl-4- 315-316 ethanol morpholino-thicnol 3.2-d lpyrimidine -2HC1 Z-[S-aminopentylaminoI-6-methyl-4- 302-305 ethanol morpholino-thicnol 3,2-d Ipyrimidinc -2HC1 TABLE lV Continued Melting Solvent of PRODUCT Point Crystallizain "C tion 2-( Z-aminoethylamino) 7-mcthyl 290 methanol 4-morpholino-thicno( 3.2-d] (decomp) pyrimidinc-ZHCI 2-( S-aminopcntylamino )-7-mcthyl- 250 ethanol 4-morpholino-thicnol3,2-d1Pyrimidine-ZHCl 2(2-aminoethylaminol-4-methylamino 280 ethanol thieno( 3.2-d )pyrimidine-ZHCI (decomp) acetone( l-3) 2-(4-aminobutylamino) 4-methylamino 300 ethanol thicnol3.2-dlpyrirnidinc-2HCI (decomp) acetone 2 (fi-aminohcxylamino)-4-methylamino- 241 ethanol thicno[3.2-d]pyrimidine2HCl acetone 2( Z-aminoethylamino )-4--n-propyl- 246-247 ethanol amino-thienol 3.2-d]pyrimidinc2HCl acetone l-3) 2 Z-aminoethylamino l-4-diethylamino- 165- l 66 methanolthieno[3.2dlpyrimidinc-2HCI (decomp) acetone l-l) EXAMPLE 2 evaporated to dryness. The residue was triturated with h l acetateetroleum ether and vacuum A mlxture of 2.3 m 0.0l mol of 2- 2- 2O am'xmre of at y p g filtered to obtain 10 (52.3% yield) of 2-(5- aminoethylamino)-4-chloro-thienol3,2-d1pyrimidine and l5 cc of pyrrolidine was refluxed for 1 hour and the excess amine was distilled off in vacuo. The residue was taken up in a IN aqueous sodium hydroxide solution and the solution was extracted several times with methylene chloride. The combined extracts were washed with water, dried over sodium sulfate and evaporated to dryness. The non-crystalline residue was dissolved in absolute ether and the addition of etheral hydrochloric acid caused a precipitate to form which was recovered by vacuum filtration. The solid was washed with ether and then was crystallized from absolute methanol to obtain 1.2 gm (36% yield) of 2-(2-aminoethylamino)- 4-pyrrolidino-thieno[ 3,2-d1pyrimidine dihydrochloride melting at 292294C.

CALCU- 4285 %H 5.69 %N 20.83

LATED:

FOUND: 42.97 5.76 2085 EXAMPLE 3 phthalimidopentylamino)-4'morpholino-thieno[ 3,2- dlpyrimidine melting at l22l24C after crystallization from a l-l mixture of ethyl acetate petroleum ether STEP B: A solution of 2.l5 gm (0.033 mol) of hydroxylamine hydrochloride in 30 cc of ethanol was added to 15 cc of 4N methanolic sodium methylate solution and the mixture was filtered to remove precipitated sodium chloride. A solution of 3.82 gm (0.00845 mol) of the phthalimido derivative produced in Step A in 20 cc of ethanol was added to the filtrate and the reaction mixture was stirred for 2 hours at room temperature. The mixture was vacuum filtered to remove the gelatinous precipitate of the sodium salt of N- hydroxyphthalimide and the filtrate was added to meth anolic hydrochloric acid and then was evaporated to dryness. The crystalline residue was crystallized from acetone-methanol mixture to obtain 1.94 gm (58.1% yield) of 2-(S-aminopentylamino)-4-morpholinothieno[3,2-d]pyrimidine dehydrochloride melting at 254-256C.

ANALYSIS: C,,-,H,,,Cl N 05; molecular weight 39429 CALCU- 45.70 %H 0540 %N l7.79 %S 3.12 LATED: FOUND: 45.50 6.56 l7.60 8.24

pyrimidine lHC'l l,2-diamino-ethane was heated at 80"C for 30 minutes and the reaction solution was concentrated to one-half TABLE V Continued Melting Solvent for PRODUCT Point Crystalliza in C tion 2-it S-aminopentyl l-ethylamino] 236-238 ethy|acetate- -4-morpholinothieno[3,2-d] methanol pyrimidinc-2HCl (3-l) 2-((fi-aminohexyl)methylaminoI 227-228 ethanol -4-morpholinothienol 3.2-d] pyrimidine-ZHCI 2 i(o-aminohexyl)ethylaminol yellow oil eluant:

-4-morpholino-thienol3.2-d] Rf Value= methanolpyramidmelZHCl 0.5 ammonia (J-l) EXAMPLE 4 I A mixture of 3.77 gm (0.01 mol) of 2-(5- chioropentylamino)-4-morpholino-thieno[3,2- d]pyrimidine hydrochloride and 50 cc of liquid ammonia were heated at 100C in a sealed tube for 16 hours after cooling, excess ammonia was distilled off and the residue was purified by chromotography over silica gel with elution with a 6-1 mixture of methanol-ammonia. The residue was taken up in a small amount of methanol and methanolic hydrochloric acid was added thereto followed by addition of acetone which resulted in the precipitation of 2-(5-aminopentylamino )-4- morpholino-thieno [3,2-dlpyrimidine dihydrochloride which after crystallization from a acetone-methanol mixture melted at 254-256C.

Using the same process, ammonia and 2-[(5 chloropentyl)methylamino]-4-morpholino-thieno[3,2- dlpyrimidine hydrochloride was reacted to form 2- HSaminopentyl)methylamino]-4-morpholinothieno[3.2-d]pyrimidine dihydrochloride which after crystallization from a 1-2 mixture of ethanol-acetone melted at 255257Cr EXAMPLE 5 A mixture of 2.67 gm (0.01 mol) methylmercapto4-morpholino-thieno[3,2- d]pyrimidine, 65 cc of l,2-diarnino ethane and 65 cc of glacial acetic acid was refluxed for 24 hours and then the reaction mixture was poured into water and made alkaline with 30% aqueous sodium hydroxide. The aqueous phase was extracted with methylene chloride several times and the combined extracts were washed with water and evaporated to dryness. The residue, which was a mixture of 2-(2-aminoethylamino)-4- morpholino-thieno [3,2-dlpyrimidine and 2-(2- acetamidoethylamino)-4-morpholino'thieno[3,2- d]pyrimidi11e, was added to 30 cc of concentrate hydrochloric acid and the mixture was refluxed for 8 hours and then cooled. The solution was made alkaline with 30% aqueous sodium hydroxide and was extracted with methylene chloride. The organic extracts were dried over sodium sulfate and evaporated to dryness. The residue was dissolved in ether and etheral hydrochloric acid was added thereto. The resulting precipi tate was recovered by vacuum filtration and was crystallized from ethanol to obtain l.6 gm (45% yield) of 2-( Z-amino-ethylamino) 4-morpholino-thieno[ 3 ,2 dlpyrimidine dihydrochloride melting at 282283C. (decomp) EXAMPLE 6 A mixture of 2.99 gm (0.01 mol) of Z-methylsulfonyl -4-morpholino-thieno[3,2'dlpyrimidine and 25 cc of its volume in vacuo and was poured into a water-ice mixture The aqueous solution was made strongly alkaline by the addition of 30% aqueous sodium hydroxide and was then extracted several times with methylene chloride. The organic phase was washed with water, dried over sodium sulfate and evaporated to dryness. The residue was purified by chomatography and was then dissolved in absolute ether. Precipitation was effected by the addition of etheral hydrochloric acid and the product was crystallized from absolute ethanol to obtain 29 gm (82% yield) of 2-(2-aminoethylamino)- 4-morpholino-thienei3.2-dlpyrimidine dihydrochloride melting at 282283C. (decomp) EXAMPLE 7 A mixture of 2.4 gm (0.01 mol) of 2-(2- aminoethylamino)-4methylmercapto-thieno[3,2- dlpyrimidine, 50 cc of morpholine and 50 cc of glacial acetic acid was refluxed for [0 hours and was then poured into water. The aqueous solution was made alkaline with 30% aqueous sodium hydroxide solution and extracted several times with methylene chloride. The combined extracts were washed with water and evaporated to dryness. The residue, a mixture of 2-(2- aminoethylamino)-morpholino-thieno[32 d]pyrimidine and 2-(2-acetamidoethylamino)'4- morpholino-thieno[3,2-d1pyrimidine, was added to 30 cc of concentrated hydrochloric acid and the mixture was refluxed for 8 hours and then cooled. The mixture was made alkaline with 30% aqueous sodium hydroxide solution and was then extracted with methylene chloride. The methylene chloride extracts were dried over sodium sulfate and evaporated to dryness. The residue was dissolved in ether and addition of etheral hydrochloride acid caused a precipitate to form The precipitate was crystallized from ethanol to obtain L9 gm (54% yield) of 2-(Z-aminoethylamino)-4-morpholinothieno [3,2-d]pyrimidine dihydrchloride melting at 282-283C. (decomp) EXAMPLE 8 A mixture of 20 cc of morpholine and 3 14 gm (0.0l mol) of 2-(Z-acetylaminoethylamino) 4 rnethylsulfonylthienol3,2-d]pyrimidine (made by oxidation of 2-(2-acetamide-ethylamino)-4-methylmercaptothieno[3,2-dlpyrimidine with potassium permanganatc) melting 22923i( was heated at C for 30 minutes and the solution was evaporated to dryness in vacuo. The residue was added to 30 cc of concentrated hydrochloric acid and the mixture was refluxed for 8 hours and then was cooled. The mixture was made aikaline with 30% aqueous sodium hydroxide solution andwas extracted with methylene chloride. The methylene chloride was washed with water, dried over sodium sulfate and evaporated to dryness. The residue was dissolved in ether and the addition of etheral hydrochloride acid thereto caused a precipitate to form. Crystallization from ethanol gave 2.3 gm (65% yield) of 2-(2-aminoethylamino)-4-morpholinothieno(3.2- d]pyrimidine dihydrochloride melting at 282-283C (decomp) EXAMPLE 9 A mixture of 2.26 gm (0.01 mol) of 2-(2- aminoethylamino)-4-mercapto-thieno[3,2- dlpyrimidine and 40 cc of morpholine was refluxed for 50 hours and excess amine was then distilled off in vacuo. The residue was purified by chromatography over silica gel and the free base was treated with etheral hydrochloric acid followed by crystallization from ethanol to form 0.4 gm (11% yield) of 2-(2- aminoethylamino)-4-morpholino-thieno[3,2- d]pyrimidine dihydrochloride melting at 282283C. (decomp) EXAMPLE A mixture of 2.56 gm (0.01 mol) of 2-chloro-4-morpholino-thieno[3,2-d]pyrimidine and 4.08 gm (0.04 mol) of 1-acetylamino-2-aminoethane was heated at 120C for 2 hours and then cooled. The solution was poured into an ice water mixture and was extracted several times with water. The organic phase was washed with water, dried over sodium sulfate and evaporated to dryness. The residue was crystallized from isopropanol to obtain 2.5 gm (78% yield) of 2-(2- acetyl-aminoethylamino)-4-morpholino-thieno [3,2- d]pyrimidine melting at l74-l76C.

A mixture of 1.6 gm (0.005 mol) of 2-(2- acetylaminoethylamino)-4-morpholino-thieno[3,2- d]pyrimidine and cc of concentrated hydrochloric acid was refluxed for 8 hours and then was cooled. The reaction mixture was poured onto ice and made strongly alkaline with a 30% aqueous sodium hydroxide solution. The mixture was then extracted with methylnickel. The catalyst was filtered off and the filtrate was evaporated to dryness. The residue was added to water and the pH of the resulting solution was adjusted to 6 by the addition of dilute hydrochloric acid. The reaction mixture was extracted with chloroform, the aqueous phase was made alkaline and was extracted again with chloroform. The chloroform phase was dried over sodium sulfate and evaporated to dryness. The residue was dissolved in isopropanol and the addition resulted in the precipitation of 5.2 gm (39.1% yield) of 2-[(3- aminopropyl) methylamino]-4-morpholino-thieno[ 3 .2- lpyrimidine dihydrochloride which after crystallization from ethanol melted at 245248C.

By the same process, 2-[(2-cyanoethyl)ethylamino]-4-morpho1ino-thieno[3,2-d]pyrimidine and 2-[(2-cyanoethyl) n-butylamino]-4-morpholinothieno[3,2-d]pyrimidine were hydrogenated using a Raney nickel catalyst to obtain 2-[ 3- aminopropyl)ethylamino]-4-morpholino-thieno[ 3 ,2- d]pyrimidine dihydrochloride melting at 280C and 2- [(3-aminopropyl)n-butylaminol-4-morpholinothieno[3,2-d]pyrimidine dihydrochloride melting at 27928lC after crystallization from isopropanol.

EXAMPLE 12 A mixture of 2.56 gm (0.01 mol) of 2-chloro-4-mor' pholino-thieno[3,2-d1pyrimidine and 7.68 gm (0.03 mol) of 2-(p-toluene sulfonamido)-ethyl ethylamine was heated for 6 hours at 140C and after cooling, the light yellow solution was poured into water. The mixture was extracted with methylene chloride and ex' tracts were dried over sodium sulfate and evaporated to dryness. The residue was purified by chromatography over silica gel with elution with a mixture of benzene-acctone-methanol (6025-15) and evaporation of the mixed solvent to obtain 4.0 gm (87% yield) of 2-[2- (p-toluene sulfonamido)ethyl ethylamino]-4-morpholino-thieno[3,2-dlpyrimidine melting at l23-l25C after crystallization from methanol. The free base was reacted with methanolic hydrochloric acid to obtain the corresponding hydrochloride salt melting at 249-251C after crystallization (frommethanol).

CALCU- C 50.64 %H 5.67 %N 14.06 %C] 7.12 12.87

LATED:

FOUND:

EXAMPLE 11 10.7 gm (0.035 mol) of 2-[(2- cyanoethyl )methylamino ]-4-morpholino-thieno( 3 ,2- d]pyrimidine were dissolved in 200 cc of methanolic ammonia and the mixture was hydrogenated for 8 hours at room temperature with a hydrogen pressure of 100 atmospheres in an autoclave with 10 gm of Raney A mixture of 4.6 gm (0.01 mol) of 2-[2-(p-toluene sulfon amido)ethyl ethylamino]-4-morpholino-thieno [3,2-d]pyramidine and 50 cc of a 40% solution of hydrobromic acid in glacial acetic acid and 1.8 gm (0.02 mol) of phenol were heated at 60C for 6 hours and then the solvent was distilled off under reduced pressure. The residue was added to water and the solution was made strongly acidic with hydrochloric acid. The aqueous phase was extracted with ethyl ether and then was made alkaline while cooling by the addition of potassium carbonate. The solution was extracted with methylene chloride and the methylene chloride was dried over sodium sulfate and evaporated to dryness. The oily residue was added to methalonic hydrochloric acid to obtain 1.2 gm (32% yield) of 2-[(2 aminoethyl )-ethylamino]-4-morpholino-thieno[ 3,2- d]pyrimidine dihydrochloride melting at 284-285C after crystallization from ethanol.

diaminoethane were heated at 120C for 4 hours and ANAL i4 2a 2 5 i mulccuhll Weigh! .1 n the excess amine was distilled off in in vacuo. The resi 0 0. a 8353 EN [8'45 M due was purified by chromatography over silica gel FOUND: 1x 25 18.40 8.23 with elution with a 9-] mixture of methanolconcentrated ammonium hydroxide. The pure fractions were evaporated to dryness and the non- Usmg Same P hydmbwmlc aclfl glllclal crystalline residue was dissolved in excess ethanolic hyflCeUC acid was reacted Yvlth the pp p lhleno drochloric acid and the solution was evaporated by dryl l y Ohm") the Products of Table Vli ness. The residue was crystallized from a 3-] mixture of methanol-ethanol to obtain 2.6 gm (68% yield) of 2-[(2-aminoethylamino)-4-diethanolamino-7-methyl- TABLE VI thleno l3,2-d]pyrim1dme dihydrochloride melting at 7 Melting Solvent of C (dtcompl PRODUCTS Point Crystallizain C tion [5 2-ItZ-aminoethyl)methylaminol-o- 291-295 ethanol I v methyl-4-morpholino-thicnol3 2-dl ggfii g g 3 %N [8 72 pyrimidine-2H0 LATFD. 2-[(2-aminoethyl)npropylaminol 273475 methanol i 4 m0rpholino thicn0[BZdI l OUN D. 40.45 6. l 8 [8i 1 pyramidine2HCl 2(1 2-( Z-aminoethyl )isopropylaminol 278-280 ethanol 4- r 3,24 p s g gi gfi g 3.84 gm of (0.01 mol) of 2(Z-ammoethylammohdt s y gyg l 27|*274 Ethunvl diethanolammoJ-methyhthrenol3,2-dlpyrimidme di- 'gg s f fg fi hydrochloride were dissolved in 50 cc of concentrated 2-[(3-aminopropyl)ethylaminol 280 ethanol sulfuric acid and the mixture was allowed to stand for fg z g z jggg 3 days at 20C in the absence of moisture. The reaction 2-[ (3-2!minopropyl)n-propylaminol 291-293 ethan l mixture was poured into a water-ice mixture and was -4-r lgirgihohznfi-(tjt ncnnt12-111 then made alkaline with a 40% aqueous sodium hyl I'lC- pyr droxide solution. The mixture was extracted several times with methylene chloride and the combined exl f Y P tracts were washed with water, dried over sodium sulp l l lPl was ly by fate and then added to etheral hydrochloric acid. The fluxing w th concentrated hydrochlorid acid to obtam resulting precipitate f 2 2 h i 7 a 34% yield f 2-H m-991 mm l methyl4morpholino-thienol3,2-d1pyrimidine dihydmorpholmo-thi nol3 ,2-d}pyr|midme d hyd 35 rochloride was recovered by filtration, was washed with m elung at 245 C afler Crystalhzanon from a ether and crystallized from methanol to obtain 1.98 gm mlxmre of ethanolacetone- (54% yield) of the said dihydrochloride melting at 335C (decomp).

ANALYSIS: C H, Cl N,,OS; molecular weight V 380.35 CALCU- %C 44.20 %H 6.09 %S 8.43 LATED:

ANALYSlS: C ;H Cl N OS; molecular weight 366.33 FOUND: 43495 CALCU /5: 42.70 70H 5.77 WIN |9.t(l

LATED: FOUND: 42.50 5.88 18.95

EXAMPLE 13 A mixture of 2.87 gm (0.01 mol) of 2-chloro-4- Using the same procedure, the appropriate 4-diediethanolamino-"I-methyl-thienol3,2-dlpyrimidine thanolamino-thienol3 2-d]pyrimidine dihydrochloride (prepared from diethanolamine and 2,4-dichloro-7- was treated with concentrated sulfuric acid to obtain methyl-thieno [3,2'd]pyrimidine) and 10 cc of 1,2- the products of Table Vll.

TABLE V11 Melting Solvent of PRODUCTS Point Crystalliyain C tion 2-[( S-aminopropyMethyluminol 280 ethanol -4-morpholino-thicnol3.241] pyrimidinc.2HCl 2-HS-uminopentyl)cthylamino] 236-238 ethyl -4-morphulino-thicnol 3.2-d I acetate pyrimidineZHC'l methanolt 3-1) 2[(6-'.iminohcxyl)mcthylamino] 227228 ethanol -4-morpholino-thicnol 3.2-Lll pyrimidinc.2HCl 2lt4=aminohutyl)whutyluminol 280 ethanol- -4 morpho|inn-thicnul 3 .2-dl acetone pyrimidine. ZHCl Z-HZ-aminoethyllisopropylalminul 278-280 ethanol -4-morpholino-thicnu[ 3.2-dl

pyrimidineZHCl 2-l Z-aminoethylamino J-4-murpholino 2X 2-28 3 -thicno| 3.2-(1 lpyrimidincQHCl (dccomp) TABLE VII -Continued Melting Solvent of PRODUCTS Point Crystallizain C tion 2-[2-aminoethylamino)-6-methyl 309-3l l methanol -4-morpholino-thieno[ 3,211} (decomp) pyrimidinc.2HCl 2-[ 2-aminoethyl )methylaminol 275 ethanol -4-morpholino-thieno( 3,2-dl (decomp) pyrimidine.2HCl 2-( 2-aminopropylarnin0)-4' 2 l 4-216 ethanol morphoIino-thieno[3,2-d] (decomp) pyrimidine.2HCl 2-( 3-aminopropyIamino)-4- 255-258 ethanol morpholino-thicno[3,2-d| (dccomp) pyrimidine.2HCI 2-(4-aminobutylamino)-4-mor- 245-247 methanolpholino-thienol3,2-d1pyrimi- (dccomp) methyl ethyl dine.2HCl ketone l-Z) 2-(fi-aminohcxylamino)-4- 280-282 ethanolmorpholino-thieno[ 3 2d I (decomp) acetone pyrimidine.2HCl (l-l) 2-[(5-aminopentyl)methylamino] 255-257 ethanol- -4-morpholino-thieno[ 3 ,Z-dl actone pyrimidine.2HCI (E-2) EXAMPLE 14 EXAMPLE B Using the procedure of Example 13, 2-(2- Coated tablets with 15 mg of aminoethylamino)-4-[N-( 2-hydroxyethyl)-2hydroxypropylaminol-thieno {3,2-d1pyrimidine dihydrochloride was treated with concentrated sulfuric acid to obtain 2-(2-aminoethylamino) -4-(2-methylmorpholino)- thieno[3,2-d]pyrimidine dihydrochloride melting at 276-278C(decomp) after crystallization from ethanol EXAMPLE l5 PHARMOLOGICAL EXAM PLES EXAMPLE A Tablets with 30 mg of 2-(Z-aminoethylamino)-4-morpholino-thieno[3,2- ]pyrimidine dihydrochloride COMPOSITION:

l tablct contains 2-(Z-aminoethylamino)-4-morpholino-thicno [3.2-dlpyrimidinc dihydrochloride 30.0 mg lactose 38.0 mg potato starch 26.0 mg polyvinylpyrrolidonc 5.0 mg magnesium stearate 1.0 mg

I000 mg COMPOUNDING PROCEEDURE The active ingredient was mixed with lactose and potato starch, moistened equally with a ethanolic solution of the polyvinylpyrrolidone and granulated through a l.5 mm mesh screen. The granulate was dried at 45"C and again passed through a I.0 mm mesh screen and the thus obtained granulate was then mixed with magnesium stearate and pressed into flat 7 mm tablets weighing I00 mg each.

2-( 4-aminobutylamino )-4-morpholino-thieno[ 3 ,2- d]pyrimidine dihydrochloride COMPOSITION:

I core of coated tablet contains 2-( 4-aminobutylamino)-4-morpholino-thieno- COMPOUNDING PROCEDURE The active ingredient was mixed with lactose and corn starch, moistened equally with a 20% ethanolic solution of the polyvinylpyrrolidone and granulated through a screen of [.5 mm mesh size. The granulate was dried at 45C and again passed through a 1.0 mm mesh screen. The thus obtained granulate was mixed with magnesium stearate and pressed into convex 5.0 mm cores of coated tablets weighing 40 mg. The thus obtained cores were coated according to known methods with a shell consisting essentially of sugar and talcum. The finished coated tablets were polished by means of beeswax and weighed 70.0 mg each.

EXAMPLE C Ampoules with 10 mg of 2-(2-aminoethylamino )-4-morphoIino-thieno[3,2- d]pyrimidine-dihydrochloride COMPOSITION;

l ampoule contains 2-(2-aminoethylamino)-4-morpholino-thieno- [3,2-dlpyrimidinc dihydrochloride I00 mg polyethylene glycol 600 100.0 mg distilled water ad 2.0 cc

uid was poured into brown 2 cc ampoules while nitrogen gasing and sterilized for 20 minutes at 120C.

EXAMPLE D Drops with mg of 2-(4 aminobutylamino)-4-morpholino-thieno-l3,2- d]pyrimidine dihydrochloride COMPOSITION:

1 ml of drop solution contains 2-(4-aminobutylamino)-4-morpholino-thicno- [3,2-d ipyrimidine dihydrochloridc 10.0 mg cane sugar 350.0 mg sorbic acid l.0 mg cocoa essence 50.0 mg ethyl alcohol 0.2 cc polyethylene glycol 600 O.l cc distilled water ad 1.0 cc

COMPOUNDING PROCEEDURE The sorbic acid was dissolved in alcohol and mixed with the same quantity of water. Then the active ingredient was dissolved in the solution (solution 1). The sugar was dissolved in the remaining water (solution 2).

Solution 2, polyethylene glycol 600 and the cocoa essence were added to solution 1 while stirring and the resulting solution was filtered through a suitable filter.

1 ml of drop solution contained 10 mg of 2-(4-' aminobutylamino)-4-morpholino-thieno[3,2- dlpyrimidine dihydrochloride. The production, filling and storage of the solution must be done under a nitrogen atmosphere.

PHARMACOLOGICAL STUDY lNHlBlTION OF PLATELET AGGREGATION The inhibition of platelet aggregation was determined by three different methods. The first method was that of K. Breddin {Schweiz. Med. Wschr. Vol 95, 655-660 (1965)] wherein human blood plasma rich in platelets was, after the addition of the test compound, slowly rotated in a water bath. A siliconized glass holder was subsequently covered with the rotated plasma, washed, fixed and colored. The inhibition of the aggregation of the platelets was determined microscopically.

The second method for the determination of the inhibition of platelet-aggregation was that of Born et al. [J. Physiol. Vol. 170, 397 (1964)]. The aggregation was measured in the plasma rich in platelets of healthy test persons. The decrease of the optical density in the suspension of platelets was measured and registered photometrically after addition of adenosin-diphosphate (10""m0ls per liter). The active substances were eac added 10 minutes before the addition of adenosindiphosphate.

The third test for aggregation of platelets was that of Morris l. lnternationales Symposium ueber Stoffwechse] und Membranpermeabilitat von Erythrozyten und Thrombozyten, Wien 1968, E. Deutsch, E. Gerlach, K. Moser; Georg Thieme-Verlag Stuttgart]. Human citrated blood was brought into contact for 30 seconds with 1 gm of glass-balls. After the contact the blood was allowed to stand for 1 hour to render possible the desaggregation ofthe reversible aggregates. The platelets in the plasma were counted microscopically before and after the contact with glass-balls.

According to these 3 test methods, the following substances showed a good inhibition of the aggregation of platelets still at a concentration of l0 mols per liter:

2-[(5-aminopentyl)ethylaamino]-4-morph0linothieno [3,2d]pyrimidine dihydrochloride. 2-[(S-aminopentyl)methylaminol-4-morpholinothieno [3,2-d1pyrimidine dihydrochloride. 2-[(3 aminopropyl)ethylaminol-4-morpholinothieno [3,2-d1pyrimidine dihydrochloride. 2[(Z-aminoethyl)ethylamino]-4 morpholino-thieno [3,2-d]pyrimidine dihydrochloride. 2-(2-aminoethylamino) Lmorpholino-thieno dlpyrimidine dihydrochloride.

2-(3-aminopropylamino)-4-morpholino-thieno [3,2-

dlpyrimidine dihydrochloride. 2-(4-aminobutylamino)-4-morpholino-thieno dlpyrimidine dihydrochloride. 2-[(2-animoethyl)methylaminol-4-morpholinothieno [3,2-d1pyrimidine dihydrochloride and 2-(2-aminopropylamino)-4-morpholino-thieno [3,2-

d]pyrimidine dihydrochloride.

Various modifications of the compositions and methods of the invention may be made without departing from the spirit or scope thereof and it is to be understood that the invention is to be limited only as defined in the appended claims.

We claim:

1. A pharmaceutical dosage unit composition consisting essentially of an inert pharmaceutical carrier and an effective platelet inhibiting amount of a compound of the formula j-m o wherein R is hydrogen or methyl,

R is hydrogen, methyl or ethyl,

R is hydrogen, 6-methyl or 7-methyl, and

A is straight or branched alkyl of 2 to 6 carbon atoms, or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

2. A composition of claim 1, wherein said compound is selected from the group consisting of 2-| (5- aminopentyl )ethylamino] -4-morpholino-thieno[ 3,2- dlpyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.

3. A composition of claim 1, wherein said compound is selected from the group consisting of 2-[(5- aminopentyl)methylamino] 4-morpholino-thieno{3.2- dlpyrimidine and its non-toxic, pharmaceutically ac ceptable acid addition salts.

4. A composition of claim 1, wherein said compound is selected from the group consisting of 2-{(3- aminopropyl)-ethylaminol-4-morpholino-thienol3,2- dlpyrimidine and its non-toxic, pharmaceutically ac ceptable acid addition salts.

5. A composition of claim 1, wherein said compound is selected from the group consisting of 2-[(2- aminoethyl )ethylamino -4 morpholino-thieno{ 3 ,2- d]pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.

6. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(2- aminoethylamino )-4-morpholino-thieno[ 3,2- d]pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.

7. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(3-,

aminopropylamino)-4-morpholino-thieno[3,2- d]pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.

8. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(4- aminobutylaminol-4-morpholino-thienol 3 ,2- dlpyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.

9. A composition of claim 1, wherein said compound is selected from the group soncisting of 2-[(2- aminoethyl )methylamino]-4-morpholino-thieno[ 3 ,2- d]pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.

10. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(2- aminopropylamino )-4-morpholino-thieno[ 3,2- d]pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.

R, is hydrogen or methyl,

R is hydrogen, methyl or ethyl,

R is hydrogen, 6-methyl or 7-methyl, and

A is straight or branched alkyl of 2 to 6 carbon atoms, or a non-toxic, pharmaceutically acceptable acid addition salt thereof. 

1. A PHARMACEUTICAL DOSAGE UNIT COMPOSITION CONSISTING ESSENTIALLY OF AN INERT PLATELET INHIBITING AMOUNT OF COMPOUND OF THE FORMULA 2-(H2N-A-N(-R2)-),4-(R1-MORPHOLINO),R3-THIENO(3,2-D)PYRIMIDINE WHEREIN R1 IS HYDROGEN OR METHYL, R2 IS HYDROGEN, METHYL OR ETHYL, R3 IS HYDROGEN, 6-METHYL OR 7-METHYL, AND A IS STRAIGHT OR BRANCHED ALKYL OF 2 TO 6 CARBON ATOMS, OR A NON-TOXIC, PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF.
 2. A composition of claim 1, wherein said compound is selected from the group consisting of 2-((5-aminopentyl)ethylamino) -4-morpholino-thieno(3,2-d)pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.
 3. A composition of claim 1, wherein said compound is selected from the group consisting of 2-((5-aminopentyl)methylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.
 4. A composition of claim 1, wherein said compound is selected from the group consisting of 2-((3-aminopropyl)-ethylamino) -4-morpholino-thieno(3,2-d)pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.
 5. A composition of claim 1, wherein said compound is selected from the group consisting of 2-((2-aminoethyl)ethylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.
 6. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(2-aminoethylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.
 7. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(3-aminopropylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.
 8. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(4-aminobutylamino)-4-morpholino-thieno( 3,2-d)pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.
 9. A composition of claim 1, wherein said compound is selected from the group soncisting of 2-((2-aminoethyl)methylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its non-toxic, pharmaceutically acceptable acid addition salts.
 10. A composition of claim 1, wherein said compound is selected from the group consisting of 2-(2-aminopropylamino)-4-morpholino-thieno(3,2-d)pyrimidine and its nontoxic, pharmaceutically acceptable acid addition salts.
 11. The method of inhibiting platelet aggregation in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective platelet aggregation inhibiting amount of a compound of the formula 